CLINICAL TRIALS PROFILE FOR MUTAMYCIN
✉ Email this page to a colleague
All Clinical Trials for MUTAMYCIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003018 ↗ | S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 1997-09-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed. |
| NCT00003018 ↗ | S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer | Completed | Southwest Oncology Group | Phase 2 | 1997-09-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed. |
| NCT00734994 ↗ | Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer | Completed | Mark Dewhirst | Early Phase 1 | 2008-04-01 | Hypothesis: In selected patients external hyperthermia will be used in combination with intravesical Mitomycin-C (MMC) to treat recurrent transitional cell carcinoma (TCC) of the bladder after local resection and standard adjuvant therapy and thus prevent or delay recurrence and the need for radical cystectomy. |
| NCT01004978 ↗ | Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | Active, not recruiting | National Cancer Institute (NCI) | Phase 3 | 2009-10-28 | This randomized phase III trial studies chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride, mitomycin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemoembolization kills tumor cells by carrying drugs directly into blood vessels near the tumor and then blocking the blood flow to allow a higher concentration of the drug to reach the tumor for a longer period of time. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving chemoembolization together with sorafenib tosylate is more effective than chemoembolization alone in treating patients with liver cancer. |
| NCT01017640 ↗ | Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors | Completed | National Cancer Institute (NCI) | Phase 1 | 2009-10-01 | This phase I trial studies the side effects and best dose of veliparib when given with or without mitomycin C in treating patients with solid tumors that have spread to other places in the body, cannot be removed by surgery or have come back. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with mitomycin C may kill more tumor cells. |
| NCT02199327 ↗ | Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia | Completed | Instituto Mexicano del Seguro Social | Phase 4 | 2014-05-01 | The purpose of this study is to evaluate the therapeutic efficacy of interferon alfa 2b and topical mitomycin C in patients with diagnosis of conjunctival-corneal intraepithelial neoplasia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MUTAMYCIN
Condition Name
| Condition Name for MUTAMYCIN | |
| Intervention | Trials |
| Stage III Bladder Cancer AJCC v8 | 3 |
| Stage IIIA Bladder Cancer AJCC v8 | 3 |
| Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall | 2 |
| Bladder Urothelial Carcinoma | 2 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for MUTAMYCIN
Trials by Country
Clinical Trial Progress for MUTAMYCIN
Clinical Trial Phase
Clinical Trial Sponsors for MUTAMYCIN
Sponsor Name
